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ABSTRACT 
     Neuronal ceroid lipofuscinoses (NCL) are the most common inherited progressive 
encephalopathies of childhood. One of the most prevalent forms of NCL, Juvenile neuronal 
ceroid lipofuscinosis (JNCL) or CLN3 disease (OMIM: 204200) is caused by mutations in the 
CLN3 gene on chromosome 16p12.1. Despite progress in the NCL field, the primary function 
of ceroid-lipofuscinosis neuronal protein 3 (CLN3) remains elusive. In this study, we aimed to 
clarify the role of human CLN3 in the brain by identifying CLN3-associated proteins using a 
Tandem Affinity Purification coupled to Mass Spectrometry (TAP-MS) strategy combined with 
Significance Analysis of INTeractome (SAINT). Human SH-SY5Y-NTAP-CLN3 stable cells 
were used to isolate native protein complexes for subsequent TAP-MS. Bioinformatic 
analyses of isolated complexes, yielded: 58 CLN3 interacting partners (IP) including 42 novel 
CLN3 IP, as well as 16 CLN3 high confidence interacting partners (HCIP) previously identified 
in another high-throughput study by Behrends et al., 2010. Moreover, 31 IP of ceroid-
lipofuscinosis neuronal protein 5 (CLN5), were identified (18 of which were in common with 
the CLN3 bait). Our findings support previously suggested involvement of CLN3 in 
transmembrane transport, lipid homeostasis and neuronal excitability, as well as link it to G-
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1. INTRODUCTION 
 Proteins rarely function in isolation but rather as macromolecular complexes that 
orchestrate cellular processes. Moreover, protein complexes are dynamic entities with spatial 
and temporal variation in composition, depending on their cellular environment 1. 
Consequently, and through implication by association, the function and cellular localisation of 
previously characterised interactors of a protein will inform on its function, pathway and 
localisation within the cell. Particularly, the design of protein interaction networks offers clues 
about disease processes or mechanisms of action, which may be exploited for therapeutic 
applications.  
Yeast two hybrid (Y2H) and tandem affinity purification coupled to mass 
spectrometry (TAP-MS) are the two most widely used experimental techniques to measure 
protein-protein interactions (PPI) 2-7. Both have been used to generate large-scale PPI 
networks for human 5-10 and several model organisms including C. elegans 11, 12, D. 
melanogaster 13, 14 and S. cerevisiae 3, 15. Although, Y2H technology is the most standardised 
technique in identifying and mapping PPI, it requires stringent criteria for screening and 
rigorous validation of hits 6, 7. In contrast, TAP-MS is an efficient and gentle method to isolate 
protein complexes from cells at near to physiological levels 16, 17. It is however biased towards 
proteins that bind with high affinity and have slow kinetics of dissociation 18. PPI obtained from 
Y2H or TAP-MS are typically further validated by several biochemical, genetic or physical 
methods, in an effort to increase confidence in the dataset 18. The various methods for 
mapping PPI generate complementary rather than overlapping data 19, 20. 
Neuronal ceroid lipofuscinoses (NCL) are characterised by early accumulation of 
auto-fluorescent storage material in lysosomes of neurons or other cells and degeneration of 
cortical neurons. Clinically, NCL patients suffer from progressive loss of vision, mental and 
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motor deterioration, epileptic seizures and premature death 21. NCL are caused by nearly 400 
mutations (mostly autosomal recessively inherited) in thirteen known genes (CLN1-8, CLN10-
14; http://www.ucl.ac.uk/ncl) and have an estimated incidence of 1 case per 12,500-200,000 
persons, in the USA and Northern Europe 21, 22. Mutations in the CLN3 gene, which encodes 
a hydrophobic integral membrane protein of 438 amino acids, are known to cause Juvenile 
neuronal ceroid lipofuscinosis (JNCL) or CLN3 disease (OMIM: 204200) 21, 23. CLN3 disease 
is the most common of all NCL 23, 24. In neurons, the CLN3 protein is primarily localised in 
endosomes / lysosomes and transported to synaptosomes 24.  
Despite extensive efforts to elucidate the functions of CLN3 using several models 
such as yeast, mammalian cells, mouse, and Drosophila 8, 25-42, there is still no consensus on 
the function of CLN3. Recently, CLN3 was shown to interact with Rab7 and RILP 41, whereas 
earlier studies reported CLN3 interactions with: myosin IIB 28, Shwachman-Bodian Diamond-
Syndrome (SBDS) 42, ß-fodrin and Na+-K+-ATPase complex 40, calsenilin 26, and Hook1 33. 
Experiments in yeast (S. cerevisiae and S. pombe) implicated CLN3 in endosome-Golgi-
retrograde transport 31, vacuole protein sorting 27, vacuolar pH homeostasis and arginine 
transport 32, 36. Moreover, investigations in mammalian cells and mouse models showed 
involvement of CLN3 in intracellular trafficking 33, 34, 41, lipid metabolism 30, 35, galactosyl-
ceramide transport 38, sphingolipid homeostasis 38, autophagy 8, 25, lysosomal arginine 
transport 37, pH homeostasis 29, and apoptosis 43. 
Thus far, a majority of PPI networks generated using affinity tagging and mass 
spectrometry in mammalian cells, were established in cancer cell lines of non-neuronal 
lineage. However, in a few recent publications (generation of muscarinic receptors 
interactome or identification of binding partners of clustered protocadherins in the nervous 
system) cells of neuronal origin have been utilised 44, 45. To gain further insight into the 
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mechanistic and biological functions of human CLN3 in the brain, we mapped its protein 
interaction network in human neuroblastoma cells. Our approach involved generation of SH-
SY5Y-NTAP-CLN3 stable cells, which were processed and analysed by TAP-MS. We used a 
recently developed Significance Analysis of INTeractome (SAINT) algorithm 46 that relies on 
statistical analysis of spectral count distributions to discern true interactions from false ones. 
Based on this statistical platform, we identified 58 CLN3 interacting partners (IP), including 42 
novel CLN3 IP. Our data confirm previously reported interactions of CLN3 with Na+/K+ 
ATPase 40, IMMT, GCN1L1, PRKDC, XPO1, CPT1A, HSD17B12, RPN2, PHGDH, COX15, 
SLC25A11, DDOST, AUP1, KIAA0368, SLC25A22, SLC25A10 and NUP205 8. Functional 
annotation using Gene Ontology (GO)_biological process of the CLN3 IP by Database for 
Annotation, Visualization and Integrated Discovery (DAVID, 
http://david.abcc.ncifcrf.gov/tools.jsp) 47 software, revealed known CLN3-associated functional 
modules (transmembrane transport, lipid biosynthetic process and nitrogen compound 
biosynthetic process) and a novel one, generation of precursor metabolites and energy. 
 
2. EXPERIMENTAL PROCEDURES 
2.1. DNA expression constructs 
Full length CLN3 (IOH3475) and CLN5 (OCABo5050F1210) entry clones 
purchased from Source BioScience UK Limited (Nottingham, UK), were shuttled in pCeMM-
NTAP(GS)-Gw (NTAP) 48 and pES-CTAP-Puro (CTAP-Puro, Supplementary Material), 
respectively, for TAP-MS experiments. Recombination of DNA fragments was performed 
using the LR clonase reaction (Life Technologies Europe BV, Espoo, Finland) and analysed 
with BsrGI restriction enzyme. Full length entry clones for co-immunoprecipitation 
experiments: CLN3 (IOH3475), DBH (OCAAo5051B0535D), DPM1 (IOH7445) and SEC61A1 
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(OCABo5050C1119D) were purchased from Source BioScience UK Limited; SLC25A10 
(RZPDo839F08152), SLC25A11 (RZPDo839G0296) and SLC25A22 (RZPDo839E0876) 
were kind gifts from Prof. Erich Wanker (MDC, Berlin). They were shuttled into 
pcDNA3.1/nV5-Dest (Life Technologies Europe BV), pcDNA3.1-ProtA-D57 (E. Wanker) 
Gateway vectors and similarly processed as indicated above. 
 
2.2. Retroviral production, transduction and generation of stable cell lines 
For producing retroviral particles, DNA of retroviral vectors was introduced into 
HEK 293T cells 49, 50 simultaneously with two packaging plasmids: pCMV-Gag-Pol vector 
(expresses gag protein and reverse transcriptase of Moloney murine leukemia virus) 51 and 
pVSV-G (expresses protein G of vesicular stomatitis virus) 52. The three plasmids were mixed 
in proportions of 7.5:5:1, respectively and introduced into cells using the calcium phosphate 
method according to the manufacturer’s protocol (Life Technologies Europe BV). Cell-free 
virus was harvested two days post transfection, filtered through 0.45 ?m pore size filter 
(Millex-HV Filter Unit, Millipore, Ireland Ltd) and used to infect low passage (P5-10) SH-SY5Y 
cells. Cells were grown in DMEM: F12 Ham’s media (1:1), supplemented with Penicillin (100 
µg/ml), Streptomycin (100 µg/ml), Glutamine, non-essential amino acids (1x) and 10% FBS 
(Life Technologies Europe BV), at 37°C under humidified atmosphere of 95% air and 5% 
CO2. Stable integrants were selected by sorting GFP positive cells using flow cytometry and 
confirmed with immunocytochemistry and Western blot analysis (see section 2.4 and 
Supplementary Material). Stably infected cells were maintained in an undifferentiated state (? 
80% confluence) and constantly checked for consistent growth rates and morphological 
features. 
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2.3. Cell culture, transfection and co-immunoprecipitation assay 
HEK 293 cells were maintained in DMEM, supplemented with Penicillin (100 
µg/ml), Streptomycin (100 µg/ml), Glutamine and 10% FBS, at 37°C under humidified 
atmosphere of 95% air and 5% CO2. Pairs of V5-CLN3 IP and PA-CLN3 tagged constructs (or 
vice versa) were transiently co-transfected in HEK-293 cells in 24 well plate format, using 
Fugene HD transfection reagent (Roche Diagnostics Oy, Espoo, Finland) according to the 
manufacturer’s instructions. After 48 h, transfected cells were harvested with lysis buffer (50 
mM HEPES, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 1 mM DTT and 10% 
glycerol) supplemented with benzonase (E1014, 250U), protease inhibitors: 1 mM PMSF 
(P7626; Sigma-Aldrich Finland Oy, Helsinki, Finland) and 1 x protease inhibitor cocktail (Cat. 
No. 04693116001, Roche Diagnostics Oy), for 30 min. Handling and processing of samples 
was done at 4°C. Cytoplasmic extracts were analysed by SDS-PAGE to control for uniform 
gene expression profiles, prior to isolation of protein complexes from 100 µl cell extracts 
incubated with shaking on 10 µl Dynabeads M-280 Sheep anti-Rabbit IgG (11204D; Life 
Technologies Europe BV), for 1 h. Bound beads were washed thrice with 100 µl minimum 
lysis buffer, resuspended in 25 µl PBS and an equal volume of 2x sample loading buffer. 
Mouse monoclonal anti-V5 (R960-25; 1:5,000, Life Technologies Europe BV) was used to 
probe for co-immunoprecipitation with CLN3. 
 
2.4. Western Blotting and Antibodies 
Primary antibodies used were: rabbit polyclonal anti-CLN3 (ab75959, 1:700), 
mouse monoclonal anti-Myc [9E10] (ab32, 1:1000), and mouse monoclonal anti-LAMP 1 
[H4A3] (ab25630, 1:300) (Abcam plc, Cambridge, UK); rabbit polyclonal anti-CLN5 [C/32]  
(1:500) 53; mouse monoclonal anti-V5 (R960-25, 1:5,000; Life Technologies Europe BV); 
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rabbit polyclonal anti-PA (5500-100; 1:10,000, Biovision, Germany); and mouse monoclonal 
anti-?-actin [AC15] (A1978, 1:1000) (Sigma-Aldrich Finland Oy). Each antibody was used 
according to the manufacturer's protocols.  
 
2.5. TAP tag purification 
Monolayer cells were harvested from five 150 mm plates of NTAP-CLN3 or 
CLN5-CTAP-IRES-Puro infected SH-SY5Y cells, grown to 80% confluency (1 × 108 cells). 
Cells were washed thrice with ice cold 1x PBS, flash frozen and lysed in 5ml Lysis buffer (50 
mm HEPES, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, and 10% glycerol) 
supplemented with benzonase nuclease (250U, E1014) and protease inhibitors (1 mM PMSF 
and 1x protease inhibitor cocktail), for 30 min at 4°C. Cytoplasmic extraction from the cell 
lysates was done by centrifugation at maximum speed (18,000 rpm) for 10 min., thereby 
pelleting cell nuclei. The supernatant was used for batch purification of the IgG binding 
domain (TAP)-tagged protein complexes using 200 ?l of packed IgG-Sepharose 6 Fast Flow 
resin (Amersham Biosciences). Lysates were incubated with resin for 3 h at 4°C, washed 
thrice with 500 ?l of 1x TBS-MNGZ (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 2.5 mM MgCl2, 
0.1% NP-40, 10% glycerol) and TEV cleavage buffer (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 
0.1% NP-40, 0.5 mM EDTA, 1 mM DTT). Tagged proteins were cut off the beads using 200 
units of TEV protease (Life Technologies Europe BV) in a 300 ?l reaction for 16 h, at 4 °C. 
TEV protease cleaved protein complexes, were eluted with 500 ?l of 1x TBS-MNGZ and 
collected. The TEV eluates were incubated with 200 ?l of packed Streptavidin beads (Sigma-
Aldrich Finland Oy), previously washed with 1 ml of 1x TBS-MNGZ, for 4 h at 4 °C. Bound 
Streptavidin resin was washed thrice with 500 ?l of 1x TBS-MNGZ and competitively eluted 
by 2.5 mM Biotin diluted in TBS-MNGZ, with gentle end-over-end rotation for 30 min at 4 °C. 
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2.6. Sample preparation and nano-LC/ESI/MS/MS analysis 
Streptavidin eluates (purified protein complexes) were reduced in 20 mM 
ammonium bicarbonate (Sigma) with 10 mM DTT (Sigma), 2 mM TCEP (Life Technologies 
Europe BV) (45 min. at 56°C) and alkylated with 55 mM iodoacetamide (Sigma; 30 min. at 
room temperature, in the dark), prior to TCA / Acetone precipitation. Pellets were dried and 
solubilised in 0.05% RapiGest SF (186002122; Waters AB, Sweden) by incubation at 60 °C 
for 30 minutes. Samples were digested overnight with sequencing Grade Modified Trypsin 
(0.25 - 0.5 µg, V5111, Promega AB), at 37 °C with gentle agitation. The peptide mixture was 
applied to RP-18 precolumn (nanoACQUITY Symmetry® C18, 186003514; Waters AB) using 
water containing 0.1% TFA as mobile phase and then separated on a nano-HPLC RP-18 
column (nanoACQUITY BEH C18, 186003545; Waters AB) with an acetonitrile gradient (0 % 
- 60 % ACN in 120 min.), in the presence of 0.05% formic acid at a flow rate of 150 nl/min. 
The column outlet was directly coupled to the ion source of the spectrometer working in the 
regime of data dependent MS to MS/MS switch. A blank run ensuring lack of cross 
contamination from previous samples preceded each analysis.  
 
2.7. Bioinformatic analyses 
For details of bioinformatic analyses please see Supplementary material. The networks were 
drawn using Cytoscape software (http://www.cytoscape.org/) 54. 
 
3. RESULTS 
3.1. Establishment of SH-SY5Y stable cells and processing of protein complexes 
In order to determine CLN3 IP, we opted for an unbiased five step approach as 
follows: construction of mammalian retroviral based expression vectors, generation of stably 
Scifo et al. 2013 Drafting the CLN3 Interactome 
 10
expressing cell lines, Tandem Affinity Purification (TAP), shot-gun sequencing of isolated 
protein complexes and functional annotation / interactome analysis (Figure 1).  
[Suggested location for Figure 1] 
 
The pCeMM-NTAP(GS)-Gw vector (EUROSCARF; http://web.uni-
frankfurt.de/fb15/mikro/euroscarf/index.html) used in this study has previously been described 
by Bürckstümmer et al. 48. It has retroviral packaging, a property that was exploited to infect 
SH-SY5Y cells and also contains a Green fluorescent protein (GFP) cassette which allows for 
selection of GFP positive cells by flow cytometry. We determined partial sub-cellular 
localisation of the CLN3 protein in lysosomes and confirmed successful generation of SH-
SY5Y-NTAP-CLN3 stable cells, by immunofluorescence confocal microscopy (Figure 2A) and 
Western blot analysis (Figure 2B). Empty SH-SY5Y cells and SH-SY5Y-NTAP (empty vector) 
cells served as negative controls. 
 Two bands (at approx. 60 and smear at 75 kDa; Figure 2B, right), visible on the 
SH-SY5Y-NTAP-CLN3 lane and absent in the negative controls (SH-SY5Y and SH-SY5Y-
NTAP cells) were attributed to glycosylated full-length, tagged CLN3 protein (isoform 1, 438 
aminoacids), predicted to migrate about 75 kDa and its un-glycosylated form (at approx. 60 
kDa), respectively. It is known that CLN3 is heavily N-glycosylated 55, 56 and typically proteins 
with this modification tend to migrate at a higher molecular weight than their theoretical 
values. Endogenously expressed CLN3 in SH-SY5Y cells is undetectable by available CLN3 
antibodies and as such no signal of CLN3 was observed in negative controls. 
[Suggested location for Figure 2] 
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Additionally, the vector consists of an N-terminal TAP tag: 2 Protein G, Tobacco 
etch virus (TEV) site and Streptavidin binding peptide (SBP) domains, which facilitate tandem 
affinity purification 48. This feature was utilised to isolate protein complexes from the SH-SY5Y 
stable cells by Tandem Affinity Purification (TAP; various procedure steps are shown in 
Supplementary Figure 1A-B), prior to analysis using reverse phase nano-flow Liquid 
chromatography Electrospray Ionisation coupled to tandem mass spectrometry (reverse 
phase nano-LC/ESI/MS/MS).  
 
3.2. Identification of Novel CLN3 IP 
Protein identifications of CLN3 IP (Table 1) are derived from three independent 
TAP-MS experiments, in which native protein complexes were isolated from SH-SY5Y-NTAP-
CLN3 stable cell lines. SH-SY5Y-NTAP (empty vector) served as the negative control. Bait 
recovery of tandem affinity purified SH-SY5Y-NTAP-CLN3 (Supplementary Figure 1A) 
indicates an average of 8 peptides with 26% coverage, for the CLN3 protein (Supplementary 
Figure 1B). All negative control samples (NTAP) showed no evidence of CLN3 detectable by 
mass spectrometry (MS). Fragment ion spectra from two representative peptides detectable in 
the NTAP-CLN3 purified protein complex are depicted in Supplementary Figure 1C. 
Identifications were accepted for proteins appearing in at least two experiments with an 
average of individual probabilities for SAINT analysis (AvgP SAINT) ? 0.50, after exclusion of 
contaminants (proteins that bind non-specifically to empty vector alone and previously 
observed TAP contaminants) 48, 57. Additionally, single protein hits were considered positively 
identified at a higher threshold of AvgP SAINT ? 0.90. 35 proteins were in the first category, 
and 23 in the latter. In total, 58 CLN3 IP were identified in this study, including 42 novel CLN3 
IP and 16 CLN3 high confidence interacting partners (HCIP) previously determined by 
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Behrends et al. 2010 8. The unfiltered list of proteins isolated from SH-SY5Y-NTAP-CLN3 
stable cells is shown in Supplementary Table 1. 
[Suggested location for Table. 1] 
 
3.3. Validation of selected CLN3 IP by co-immunoprecipitation and 
immunofluorescence co-localisation with CLN3 
In order to determine physical interactions of CLN3 with selected IP, we chose 6 
CLN3 IP identified by MS (including four of the previously identified CLN3 HCIP in HEK 293 
cells 8) on the basis of their known biological functions or entry clone availability and 
performed co-immunoprecipitation experiments in HEK 293 cells (Figure 3). This model was 
chosen since SH-SY5Y cells are slow growing, and thus not very well suited for medium 
throughput co-immunoprecipitation experiments as opposed to fast growing HEK 293 cells. 
Moreover, several high-throughput PPI network studies utilised HEK 293 cells in large scale 
co-immunoprecipitation validation experiments in the past, e.g. 8, 10, 58. HEK 293 also served 
as a model in a recent article on autophagy 8, where several partners of CLN3 were detected. 
The chosen proteins included: two novel CLN3 IP, dopamine beta hydroxylase (DBH), 
selected for its involvement in the neurological disorders (Supplementary Tables 2 and 3) and 
dolichol-phosphate mannosyltransferase (DPM1), selected for its role in N-glycosylation and 
O-mannosylation of proteins.  
[Suggested location for Figure 3] 
 
In summary, co-immunoprecipitation analysis (Figure 3) confirmed CLN3 physical 
interactions with DBH, DPM1, SEC61A1 and SLC25A10. We were unable to detect specific 
interactions of CLN3 with SLC25A11 and SLC25A22 (data not shown), which suggests that 
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these interactions may require more specific conditions that were absent in our experimental 
setup. Alternatively, tagging might have interfered with the interaction. Probing with mouse 
monoclonal anti-V5 and rabbit polyclonal anti-PA antibodies confirmed approx. 70% of the 
selected CLN3 IP observed in TAP-MS experiments, including 2 that are common IP to both 
CLN3 and CLN5 baits. 
We further performed in vivo subcellular co-localisation studies in SH-SY5Y cells 
to examine the spatial overlap between DBH, DPM1, SEC61A1, SLC25A10 and CLN3. SH-
SY5Y-NTAP-CLN3 stable cells were transiently transfected with the CLN3 IP and analysed 
for co-localisation patterns by dual immunofluorescence confocal microscopy. This work 
showed CLN3 to partially co-localise with DBH, DPM1, SEC61A1 and SLC25A10 
(Supplementary Figure 2). The distribution of co-localisation points suggests that the 
interactions between CLN3 and DBH or DPM1 likely occur in lysosomes, whereas those with 
SEC61A1 and SLC25A10 are in the ER-Golgi and ER, respectively.  
 
3.4. Functional annotation of the CLN3 interactome revealed enrichment in 
transmembrane transport, generation of precursor metabolites and energy, lipid 
biosynthesis and nitrogen compound biosynthetic process 
Following the identification of CLN3 IP, there was a need to functionally annotate 
the obtained protein list and analyse the resulting CLN3 interactome. Towards this goal, we 
initiated GO analysis of the CLN3 interactome by DAVID 47, a publicly available online 
resource for comprehensive analysis and attachment of biological relevance to gene / protein 
datasets. Using the human genome as a background, this analysis yielded the following four 
most enriched GO_biological process terms: transmembrane transport (GO:0055085, fold 
enrichment: 7.0); generation of precursor metabolites and energy (GO:0006091, fold 
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enrichment: 5.9); lipid biosynthesis process (GO:0008610, fold enrichment: 5.7) and nitrogen 
compound biosynthetic process (GO:0044271, fold enrichment: 5.7; Figure 4A and 
Supplementary Table 4A). The fold enrichment of a particular GO term refers to the ratio of 
input genes / proteins associated with a specific process or function to the ratio of background 
information related to the same genes / proteins. For instance 7% of input proteins are 
associated with transmembrane transport and the background information of proteins 
associated with the same term is 1%, hence the fold enrichment of 7. Previous studies have 
implicated CLN3 in transmembrane transport 31, 32, 34, lipid biosynthesis 38, and nitrogen 
compound biosynthetic process 59, which are also supported by our findings.  
Functional clustering analysis of selected terms from GO categories, protein 
domains, multiple cellular pathways, SwissProt database terms and others (Supplementary 
Tables 4A-D) revealed that transmembrane transport was the most prominent GO_biological 
process term in the second most enriched cluster (enrichment score = 7.69, Figure 4B and 
Supplementary Table 4B). Moreover, cluster 4 (enrichment score = 3.47, Figure 4C and 
Supplementary Table 4B) included proteins enriched in Huntington’s and Parkinson’s 
diseases (KEGG pathway). Functional annotation cluster analysis relies on kappa statistics 
and fuzzy heuristic clustering, to quantitatively measure the degree of the common genes 
between two annotations terms. Genes that share a similar set of annotation terms will have a 
higher chance of being grouped together and likely be involved in similar biological 
mechanisms 47. 
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3.5. Analysis of the CLN5 interactome 
The same experimental procedures used for analysis of the CLN3 interactome, 
such as generation of stable cell lines and TAP-MS were applied to CLN5. However, pES-
CTAP-Puro (a modified version of pCeMM-CTAP(SG)-Gw vector, EUROSCARF), hereby 
referred to as (CTAP-Puro) was used instead. It is similar to the original plasmid 48, except 
that the IRES-GFP cassette has been replaced with IRES-Puro and thereby facilitating 
selection on puromycin (data not shown). The functionality of pES-CTAP-Puro was verified by 
successful cloning and expression of human CLN5 (Supplementary Figure 3). In this study, 
no NCL proteins were observed to co-purify with either the CLN3 or CLN5 baits. However, the 
identified 31 CLN5 IP included 18 proteins in common with the NTAP-CLN3 bait (Figure 5A), 
11% of which were verified by co-immunoprecipitation experiments. The common proteins to 
both CLN3 and CLN5 baits were: SLC25A4, DBH, SFXN3, RCN2, CALU, SLC25A13, 
SLC25A22, SLC25A1, ATP2A2, SLC25A5, SLC25A6, PHGDH, ARF4, SEC61A1, XPO1, 
RPN1, SLC25A11 and CDS2. A list of the CLN5 IP, isolated from SH-SY5Y-CLN5-CTAP-
Puro stable cells, is shown in Table 2 and the complete unfiltered list of proteins recovered 
from the cells is presented in Supplementary Table 5. 
[Suggested location for Table 2] 
 
3.6. Neurodegenerative disease proteins within the CLN3-CLN5 interactome are linked 
to mental retardation and epileptic seizures 
By linking the combined CLN3-CLN5 interactome to OMIM database we found 
that 8 of the IP can be assigned to a disease (Supplementary Tables 2 and 3), with 6 of them 
to a neurodegenerative phenotype. The CLN3-CLN5 interactome (Figure 5A) includes in total 
8 neurodegenerative disease causative proteins: CLN3- Batten disease, STRA6- mental 
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retardation, TECR- nonsyndromic mental retardation, DBH- schizophrenia, PHGDH- 
psychomotor retardation and seizures, SLC25A22- neonatal myoclonic epilepsy, CLN5- 
Finnish variant late infantile NCL and ATP1A3- dystonia parkinsonism. Most of these proteins 
are either involved in mental retardation or epileptic seizures, both of which are established 
clinical symptoms of NCL patients. Interestingly, 4 CLN3 IP can be further assigned to 
Huntington’s disease (KEGG pathway; hsa: 05016) and Parkinson’s disease (hsa: 05012) 
pathways (SLC25A6, SLC25A5, SLC25A4 and UQCRC2; Figure 4C, Supplementary Figure 4 
and Supplementary Tables 4B and 4D). Moreover, a functional linkage between those 
proteins and synuclein can be established (Supplementary Figure 5). It has recently been 
demonstrated that CLN3 binds directly to synuclein (SNCA) 60 and several IP from the CLN3-
CLN5 network are directly interacting with it (Supplementary Figure 5 and Supplementary 
Table 6). Other proteins of interest within the network include: ARF3, ARF4 and ARF5, which 
are GTP-ases of the RAS superfamily that have roles in vesicular trafficking and recruitment 
of coat complexes to budding vesicles. ARF3 was recently shown to be a constituent of the 
amyloid ? precursor protein (A?PP) interactome in the brain of transgenic mice expressing 
tagged A?PP 58. Moreover, FKBP8 and CANX are noteworthy for their anti-apoptotic effects / 
interactions with PSEN1 / PSEN2 and involvement in dysmyelination, respectively 61, 62. A 
more detailed CLN3-CLN5 interactome network that incorporates IP from this work and also 
includes those derived from other studies (based on literature mining and database 
knowledge) is depicted in Supplementary Figure 5, for completeness of the available 
knowledge. A total of 128 proteins including six NCL disease ones (PPT1, TPP1, CLN3, 
CLN5, CLN6, CLN8) are connected via 162 PPI. 
[Suggested location for Figure 5] 
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4. DISCUSSION 
Highly hydrophobic integral membrane proteins like CLN3 present a considerable 
challenge for interactomics studies, because they are difficult to solubilise and prone to non-
specific interactions. In this study, we employed a stringent TAP-MS strategy complemented 
by bioinformatics, SAINT analysis and co-immunoprecipitation assays, in an attempt to 
remedy these limitations and draft the CLN3 interactome in SH-SY5Y human neuroblastoma 
cells. We supplemented our lysis buffer with 1% Nonidet P-40, a nonionic non-denaturing 
detergent that is sufficient to solubilise membrane proteins without disrupting their molecular 
environment. Moreover, the SAINT statistical platform allowed us to assign confidence scores 
to PPI deduced from our TAP-MS experiments. SAINT uses label free quantitative data 
(spectral counts), to derive a probability of true interaction and is an efficient tool to discern 
true interaction partners from background noise, even in instances when the proteins are 
detected at low levels in control samples 46.  
The choice of cellular model was motivated by a need to mimic the physiological 
context of CLN3 disease, which involves degeneration of cortical neurons. As such, we chose 
SH-SY5Y human neuroblastoma cells, an established dopaminergic neuron model that has 
been extensively used for studies of Parkinson’s disease 63 and CLN3 function 26, 64, 65. 
Moreover, CLN3 patients have Parkinsonian symptoms and decreased dopamine transporter 
density in the striatum 66. Therefore, we isolated protein complexes from SH-SY5Y stable 
cells and based on three independent TAP-MS experiments, a total of 58 CLN3 IP (Table 1) 
was identified after SAINT analysis and filtration of known contaminants 48, 57. They included 
42 novel CLN3 IP and 16 CLN3 HCIP previously found by Behrends et al. 8, thereby 
confirming the reliability of our approach. TAP is especially well suited for isolation of TAP-
tagged CLN3 protein complexes, because the currently available antibodies do not detect the 
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endogenously expressed protein. It is noteworthy that PPI derived from a TAP-MS platform 
may include both direct and indirect interactors. Moreover, our draft CLN3 interactome is 
likely incomplete, since TAP technology inherently limits the recovery of more transient 
interactions during the two step affinity purification.  
In this study, we confirmed the CLN3 interaction with Na+-K+-ATPase 40 and also 
successfully reproduced 37% of the 43 CLN3 HCIP determined in a single affinity-capture MS 
dataset from HEK 293 cells 8. Other reported interactions were not verified by our TAP-MS 
approach, for several reasons. Firstly, CLN3 interactions with ß-fodrin 40, calsenilin 26, SBDS 
28, 42 and myosin IIB 28, were determined by Y2H screens and the Cytotrap Y2H system, 
respectively. Secondly, CLN3 interactions with Rab7 41, RILP 41 and Hook 1 33, were detected 
by immunofluorescence confocal microscopy in HeLa cells. This discrepancy is probably 
explained by the fact that both methodologies are significantly different from our approach 
which assays protein complexes at close to endogenous levels in human neuroblastoma 
cells.  
In order to explore further the connectivity of both CLN3 and CLN5 interactomes, 
we systematically surveyed mammalian protein complexes using Corum database 
(http://mips.gsf.de/genre/proj/corum/index.html), a collection of experimentally verified 
mammalian protein complexes. For example, SLC25A5, together with SLC25A4 and ATP5A1 
form SDH-mABC1-PIC-ANT-ATPase complex (Corum complex:139; Figure 5B), while 
ATP1A1 together with ATP1B1 are part of Na+,  K+-ATPase complex (Corum complex:3134; 
Figure 4B and C; Supplementary Table 2). ATP1B1 has previously been detected as a CLN3 
IP in yeast- two hybrid screens 67. 
Most notable of the previously identified CLN3 IP are PHGDH and SLC25A22, for 
their involvement in L-serine synthesis and neuronal excitability, respectively. 3-
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phosphoglycerate dehydrogenase (PHGDH) catalyses a critical first step in the biosynthesis 
of L-serine. The importance of L-serine in cellular metabolism is derived from its essential 
roles as a precursor for the synthesis of proteins, membrane lipids, and neuromodulators 
(glycine and D-serine). Patients with PHGDH deficiency (OMIM: 601815) are characterised by 
congenital microcephaly, psychomotor retardation, and seizures 68, 69. Mutations in the 
mitochondrial glutamate carrier SLC25A22 cause neonatal myoclonic epilepsy (OMIM: 
609304), whose symptoms include, spontaneous muscle contractions, hypotonia, 
microcephaly, abnormal optic nerve conduction, rapid evolution into general brain dysfunction 
and spasticity 70, 71. Moreover, results from patients’ fibroblasts showed that alterations in 
mitochondrial glutamate import / metabolism led to impaired neuronal excitability 72. It is 
postulated that a failure of mitochondrial glutamate transport in astrocytes leads to 
accumulation of glutamate in the cytosol and thereby neuronal synchronicity that contributes 
to epileptic seizures 70. Although, CLN3 associations with PHGDH and SLC25A22 have 
previously been shown in HEK 293 cells 8, this study provides the first such evidence in a 
neuronal-like cell line.  
Three novel CLN3 IP were of particular interest because of their involvement in 
G-protein signalling (CDS2 and PTPLAD1) and protein folding / sorting in the ER (CALU). 
CDP-diacylglycerol synthase (CDS2) encodes an integral membrane protein that catalyses 
the conversion of phosphatidic acid to CDP-diacylglycerol and is localised in both the inner 
mitochondrial matrix membrane and cytoplasmic side of the endoplasmic reticulum (ER). The 
enzyme is involved in the synthesis of phosphatidylglycerol and cardiolipin, in mitochondria 
and phosphatidylinositol biosynthesis, in the ER 73. In Cln3 deficient mouse cerebellar cells 
where autophagy was impaired 25, inositol monophosphatase inhibitors which affect the 
phosphatidyl inositol signalling pathway, partially rescued the autophagic process and 
Scifo et al. 2013 Drafting the CLN3 Interactome 
 20
reduced the neuronal vulnerability in these cells 74. Interestingly, recent work in C. elegans 
shows that synaptic polarity depends on phosphatidylinositol signalling regulated by myo-
inositol monophosphatase 75, thus potentially providing a mechanistic link between the 
observations of impaired autophagy, phosphatidylinositol signalling, synaptic failure and 
apoptosis. 
Another protein involved in signalling is Protein-tyrosine phosphatase-like A 
domain containing 1 protein (PTPLAD1), an integral membrane protein implicated in small 
GTPase mediated signal transduction and fatty acid biosynthetic process 76, 77. The third novel 
CLN3 IP, Calumenin (CALU), is a calcium binding protein that is highly expressed in various 
brain regions during development and functions in protein folding and sorting in the ER 78. 
The surveyed novel CLN3 IP, support functional roles of the protein in GTPase mediated 
signal transduction and involvement in the ER quality control machinery. Moreover, this study 
establishes a novel link between CLN3 and the regulation of cellular phospholipid content 
through its interaction with CDS2.  
An indirect interaction between CLN3 and CLN5 proteins was reported in GST-
pulldown experiments when overexpressed CLN3 and CLN5 fragments were used 79. In this 
study, a molecular link between NCL proteins is supported by the common proteins co-
purified with both CLN3 and CLN5 baits (Figure 5A). The majority of these proteins are 
mitochondrial carriers (SLC25A4, SLC25A13, SLC25A22, SLC25A1, SLC25A5, SLC25A6 
and SLC25A11), involved in neurodegenerative diseases (DBH, PHGDH and SLC25A22; 
Supplementary Table 3) or calcium binding (CALU, RCN2). Moreover, since all NCL are 
related to deposition of storage material, we systematically searched for known components 
of lipofuscin. Intriguingly, 10 proteins (14%) of the combined CLN3-CLN5 interactome are 
constituents of the lipofuscin proteome (Supplementary Table 2) 80, 81. 
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Most identified CLN3 and CLN5 IP are novel and so in order to gain more insight 
into their functional associations using network approaches, we utilised FunCoup database 
(http://FunCoup.sbc.su.se, 82) which allows for visualisation of global gene / protein networks 
of functional coupling via Bayesian integration of diverse high-throughput data. Among the 67 
out of 72 input genes present in the FunCoup, we identified 649 functionally coupled pairs 
with high confidence score (? 0.5, scale 0-1; Supplementary Table 7). 14 of the 55 (22%) 
CLN3 IP, including two novel ones (SCAMP3 and TECR) are predicted to be functionally 
coupled with CLN3 at this threshold. CLN5 is predicted to be functionally linked with CLN3 at 
a very high confidence level of 0.96 and with SEL1L protein (score = 0.93). The high number 
of links (approx. 10) per protein reflects a dense network of functional associations among the 
input genes providing further support for their involvement in similar biological processes. 
In an attempt to functionally cluster the CLN3-CLN5 bridging proteins, we also 
queried their direct IP and filtered for high expression in the brain (http://cbdm.mdc-
berlin.de/tools/hippie/information.php, 83). Several mitochondrial carriers were connected 
through proteins involved in autophagy (Supplementary Figure 6), a process in which CLN3 
has previously been implicated 8, 25. Moreover, as GABAergic neuronal populations are 
strongly affected in both CLN3 and CLN5 patients especially in the CA2-CA4 regions of the 
hippocampus 84, it is plausible that autophagic processes involving GABA-receptor associated 
proteins may be responsible for neurodegenerative processes in these brain regions. 
Previous work by Oresic et al. 2009 85 demonstrated that CLN6 (also predicted to 
interact with CLN5; overall probability score = 0.36, medium confidence range; PrePPI 
database, http://bhapp.c2b2.columbia.edu/PrePPI/ 86, 87) mutants (G123D and M241T), 
formed a complex with proteins of the ERAD pathway and could be significantly rescued with 
knockdown of SEL1L. Interestingly, several proteins of the ERAD pathway (SEL1L, OS9, 
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FBXO6 and FBX27) co-purified with the CLN5 bait. These findings indicate a functional link 
between CLN5 and CLN6, at the ER quality control. Although no NCL proteins co-purified 
with either the CLN3 or CLN5 baits, the common proteins between the two suggest that 
interactions amongst NCL proteins maybe transient. Given the underlying phenotype 




These findings demonstrate that the TAP-MS approach, combined with 
bioinformatics, SAINT analysis and co-immunoprecipitation assays is a valid platform for 
investigating interactomes of low abundance integral membrane proteins. Specifically, this 
study revealed that the combined CLN3-CLN5 interactome in SH-SY5Y human 
neuroblastoma cells includes proteins involved in neurodegeneration, mental retardation and 
epileptic seizures. The extent of crosstalk amongst disease proteins is marked and may 
suggest that the mechanisms leading to the functional deficits are shared between them. 
Here, previously suggested functional roles of CLN3 in transmembrane transport, lipid 
homeostasis and neuronal excitability, are also supported by our data. Furthermore, this 
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Figure 1: Strategy for isolation and analysis of protein complexes in SH-SY5Y human 
neuroblastoma cells.  
Human CLN3 / CLN5 entry clones were shuttled into NTAP or CTAP-Puro destination 
vectors, to generate mammalian expression vectors used to infect SH-SY5Y cells. Stably 
expressing clones were isolated by Flow cytometry or Puromycin selection, expanded and 
subjected to Tandem affinity Purification coupled to mass spectrometry (TAP-MS). CLN3 / 
CLN5 IP were identified and analysed by bioinformatics tools (Mascot and SAINT, 
respectively), prior to filtration of known contaminants. Finally, High confidence hits underwent 
Gene Ontology and pathway analysis to select targets for further biochemical and functional 
validation. 
 
Figure 2: Generation of SH-SY5Y-NTAP-CLN3 stable cells. 
(A) Immunodetection with Rabbit polyclonal anti-CLN3 (ab75959, 1:300, red) and Mouse 
monoclonal anti-LAMP1 [H4A3] (1:300, green), shows that CLN3 partially co-localises with 
the lysosomal marker, LAMP1. From top to bottom, anti-CLN3, anti-LAMP1 and overlay. 
Scale bar = 20 µm. Images were visualised on a Leica SP8 confocal microscope (Wetzlar, 
Germany). (B) Western Blot analysis of SH-SY5Y-NTAP-CLN3 stable cell lines with the CLN3 
antibody, reveals two bands (at approx. 60 and 75 kDa) that were absent in either empty SH-
SY5Y or SH-SY5Y-NTAP cells. Gly NTAP-CLN3 and UnGly CLN3 are abbreviations for 
glycosylated full-length, tagged CLN3 protein and its un-glycosylated form, respectively. 
Equal protein load was assessed with anti-??actin. 
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Figure 3: Validation of selected CLN3 IP in co-immunoprecipitation assays. 
Co-immunoprecipitation was performed in triplicates on lysates from HEK 293 cells, 
transiently expressing Protein A (PA) tagged CLN3 and V5-tagged proteins of interest. Co-
immunoprecipitates were resolved on 10% Tris-HCL SDS-PAGE and transferred to a 
nitrocellulose membrane, prior to immunodetection. Western blot analysis demonstrating the 
physical association between PA-CLN3 and V5-DBH (A), V5-DPM1 (B), V5-SEC61A1 (C) 
and V5-SLC25A10 (D). Expected molecular weight of V5-tagged constructs (in kDa): DBH- 
72; DPM1- 34; SEC61A1- 38; SLC25A10- 31. 
 
Figure 4: Functional analyses of the CLN3 interactome. 
(A) GO_biological process annotation of CLN3 IP by DAVID software, revealed the four most 
specific enriched terms: transmembrane transport; generation of precursor metabolites and 
energy; lipid biosynthesis process and nitrogen compound biosynthetic process (triple 
asterisks). ‘benj’ is used as an abbreviation for Benjamini-Hochberg corrected P-value. 
DAVID parameters of minimum count and EASE score thresholds were set at ? 5 genes / 
term and 0.05, respectively. (B) Functional Cluster analysis of CLN3 IP, Cluster 2. Annotation 
terms are ordered based on their enrichment scores associated with the group. The most 
enriched GO_biological process term in Cluster 2 is transmembrane transport. CLN3 HCIP 
(Behrends et al., 2010) 8 recapitulated in our study and novel CLN3 IP, are shown in dark and 
light green, respectively. Disease proteins are boxed in orange. Functional terms (in red), 
associated with CLN3 are related to various categories of cellular transport, mitochondrion or 
organelle membranes (29 genes, Benjamini: 3.53e-14). Green represents positive 
association, whereas an unknown relationship is shown in black. (C) Functional Cluster 
analysis of CLN3 IP, Cluster 4. Positive association and unknown relationship are shown in 
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orange and black, respectively. Proteins enriched in Huntington’s and Parkinson’s disease 
(KEGG pathway) are shown in red. The description of functional enrichments in both clusters 
is provided in Supplementary Table 4B. 
 
Figure 5: Cytoscape map of the combined CLN3-CLN5 interactome. 
(A) A total of 58 CLN3 IP and 31 CLN5 IP from three independent TAP-MS experiments, are 
shown. Nodes (circles) represent IP and the edges (lines connecting two nodes) indicate PPI. 
The thickness of edges is proportional to the total spectral counts, determined by SAINT 
analysis. CLN3 HCIP previously determined in the autophagy network by Behrends et al. 
2010 8 and novel CLN3 IP are connected by purple and red edges, respectively. CLN3 IP 
verified by co-immunoprecipitation experiments are presented as diamonds with thick edges.  
All links to CLN5 described in this work are novel (red). Neurodegenerative disease proteins 
(CLN3, STRA6, TECR, DBH, PHGDH, SLC25A22, CLN5 and ATP1A3) are highlighted in 
orange. ARFs which are part the amyloid ? precursor protein (A?PP) interactome, as well as 
FKBP8 and CANX, known to have anti-apoptotic effects, are coloured blue. Proteins of the 
lipofuscin interactome are depicted by grey asterisks. Links to known complexes are 
presented as dashed lines (description in Supplementary Table 4). (B) Network view of CLN3-
CLN5 functional complexes. Links to selected known protein complexes are portrayed as 
coloured edges. Description of known complexes is from Corum Database (Supplementary. 
Table 2). 139- SDH-mABC1-PIC-ANT-ATPase complex, 1183- CDC5L complex, 1442- 
Transporter (Ncx1)- receptor complex, 1208- Oligosaccharyltransferase OSTC-II complex, 
1209-Oligosaccharyltransferase OSTC-III complex, 5206- Pentraxin complex. Var- various 
known complexes. 
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TABLES 
Table 1: SAINT analysis of CLN3-IP recovered by TAP-MS. 
Stable cells expressing SH-SY5Y-NTAP-CLN3 were tandem affinity purified and lysates 
trypsinised using standard procedures, prior to analysis by reverse phase (C18) nano-
LC/ESI/MS/MS on an LTQ Orbitrap Velos (Thermos Velos) instrument. Proteins were 
identified with Mascot server 2.2.2 software (Matrix Sciences, www.matrix.com) against 
SwissProt 55.1 human database, followed by SAINT analysis and filtration of known 
contaminants, to generate a high confidence list of IP. Proteins with AvgP ? 0.5 in at least two 
out of three experiments or Single hits of AvgP ? 0.9 were accepted.  
 
Table 2: SAINT analysis of CLN5-IP recovered by TAP-MS. 
Stable cells expressing SH-SY5Y-CLN5-CTAP-Puro were subjected to tandem affinity 
purification coupled to mass spectrometry (TAP-MS) and processed similarly as indicated in 
Table 1. 
 
Supplementary Figure 1: Isolation of CLN3 IP by TAP and bait recovery. 
(A) Western blot analysis of the tandem affinity purified SH-SY5Y-NTAP-CLN3, showing 
various steps of purification. (B) Sequence coverage of identified CLN3 bait, indicating 
position of matched peptides in bold red. (C) Fragment ion spectra from two representative 
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Supplementary Figure 2: Immunofluorescence co-localisation of CLN3 with selected IP 
in SH-SY5Y cells. 
Human NTAP-CLN3 partially co-localises with (A) DBH, (B) DPM1, (C) SEC61A1, and (D) 
SLC25A10 in SH-SY5Y cells, as visualised by immunofluorescence on a Leica SP8 
microscope (Wetzlar, Germany). Mouse monoclonal anti-V5 and rabbit polyclonal anti-CLN3 
primary antibodies were used in combination with Alexa Fluor 488 and TRITC conjugated 
secondary antibodies, respectively. Images indicate anti-V5 (green, panel 1), anti-CLN3 (red, 
panel 2), merged staining (yellow, panel 3), co-localisation points (yellow, panel 4) and 
zoomed region (panel 5). The blue outline in panel 3 depicts zoomed area, shown in panel 5. 
Scale bar = 25µm. 
 
Supplementary Figure 3: Generation of SH-SY5Y-CLN5-CTAP-Puro stable cells. 
Western Blot analysis of SH-SY5Y-CLN5-CTAP-Puro stable cell line with anti-CLN5 and anti- 
Myc antibodies revealed a band at approx. 75 kDa corresponding to an un-glycosylated full 
length, tagged protein. The predicted size of tagged un-glycosylated CLN5 is approx. 75 kDa. 
A smear extending from 80-120 kDa (anti-CLN5) and 80-100 kDa (anti-Myc) is consistent with 
the glycosylated form of the protein. The SH-SY5Y-CTAP-Puro (empty vector) cells also show 
two faint nonspecific bands at 50 and 75 kDa, present in the immunodetection with anti-CLN5 
but absent with the anti-Myc. Endogenous CLN5 protein is not detectable with rabbit 
polyclonal anti-CLN5 [C/32] 53. The equal protein load was assessed with anti-? actin. 
 
Supplementary Figure 4: KEGG map of interactions in Parkinson’s disease. 
A dynamic map of KEGG-derived interactions relevant to Parkinson’s disease (PD; hsa: 
05012) was constructed. Identified CLN3 IP (UQCRC2, SLC25A4, SLC25A5 and SLC25A6), 
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described in our study were overlaid with known PD pathway components. A direct link to 
synuclein (SNCA) is visible. The network was visualised in Cytoscape using Cell Region-
Based Rendering And Layout (Cerebral) plug-in. 
 
Supplementary Figure 5: Comprehensive Cytoscape map of the combined CLN3-CLN5 
interactome. 
A more detailed CLN3-CLN5 protein-protein interaction network comprising of known CLN3 / 
CLN5 IP from databases and novel ones (this study) as described in the text, was visualised 
using Cytoscape 51. Nodes described in this study (yellow), those from database mining / 
literature (green) and involvement in neurodegenerative disease (orange), are highlighted. 
Disease proteins: PPT1-palmitoyl transferase 1 (CLN1), TPP1- tripeptidyl transferase 1 
(CLN2), CLN6, CLN8 and SNCA- synuclein A (Parkinson’s disease) are shown. The 
thickness of edges is proportional to the total spectral counts, determined by SAINT analysis. 
CLN3 HCIP previously determined in the autophagy network by Behrends et al. 2010 and 
novel CLN3 IP are connected by purple and red edges, respectively. CLN3 IP verified by co-
immunoprecipitation experiments (this work) are shown as diamonds with thick edges and 
CLN5 IP described in this work are in red. Other database / literature derived links are in blue. 
ARFs which are part of the amyloid ??precursor protein (A?PP) interactome, as well as 
FKBP8 and CANX, known to have anti-apoptotic effects, are coloured in blue. A list of all 
connections is given in Supplementary Table 6.  
 
Supplementary Figure 6: Brain network analysis of CLN3-CLN5 bridging proteins. 
Proteins which bridge CLN3 and CLN5 disease proteins were connected using Human 
Integrated Protein-Protein Interaction rEference (Hippie) database and filtered for high 
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expression in the brain. The medium confidence threshold (0.63 - second quartile of the 
HIPPIE score distribution) was used for assigning the confidence of interactions. Score (“-1”) - 
an interaction not found in the Hippie database. PHGDH, RCN2, SLC25A4, SLC25A5, 
SLC25A6 can be directly connected to autophagy-linked proteins (GABARAP- Gamma-
aminobutyric acid receptor-associated protein, GABARAPL1- GABA(A) receptor-associated 
protein like 1, GABARAPL2- GABA(A) receptor-associated protein like 2, MAP1LC3B- 
microtubule-associated protein 1 light chain 3 beta). CLN3 has been assigned previously to 
the same cellular process 8.  
 
Supplementary Table 1A-C: Unfiltered list of proteins isolated from SH-SY5Y-NTAP-
CLN3 stable cells (Exp. 1-3). 
Stable cells expressing SH-SY5Y-NTAP-CLN3 were subjected to tandem affinity purification 
coupled to mass spectrometry (TAP-MS) and processed similarly as indicated for Table 1, 
except that raw data is shown without filtration steps. SAINT analysis of CLN3 baits is based 
on three experiments and empty NTAP vector is used as a negative control.  
 
Supplementary Table 2: List of all CLN3 and CLN5 IP with Gene identifiers, complex 
attributes and OMIM phenotypes. 
CLN3 / CLN5 IP were linked to NCBI Gene identifiers (Gene ID); published literature 
(HCIP_autophagy, Behrends et al. 2010), published mammalian protein complexes (Corum 
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Supplementary Table 3: List of literature derived disease associations of CLN3-CLN5 
network. 
Proteins of combined CLN3 / CLN5 network were linked to literature-mined disease 
associations. The list of associations was derived from a database created by S. Frankild and 
L.J. Jensen (http://diseases.jensenlab.org/.) 
 
Supplementary Table 4A-D: Summary list of annotations of CLN3 and CLN5 IP 
identified by TAP-MS. 
(A) Summary list of GO_Biological Process classification and other functional terms of CLN3 
IP identifed by TAP-MS. Gene ontology analysis of CLN3 IP was done by DAVID software 
(http://david.abcc.ncifcrf.gov/tools.jsp). The most prominent biological process terms included: 
transmembrane transport (GO:0055085), generation of precursor metabolites and energy 
(GO:0006091), lipid biosynthesis process (GO:0008610) and nitrogen compound biosynthetic 
process (GO:0044271). (B) Functional cluster term enrichment analysis of CLN3 IP. Using 
DAVID medium stringency criteria 31 clusters can be identified. (C) Functional cluster term 
enrichment analysis of CLN5 IP. (D) List of over-represented pathways for CLN3 and CLN5 
local networks. 
 
Supplementary Table 5A-C: Unfiltered list of proteins isolated from SH-SY5Y-CLN5-
CTAP-Puro stable cells (Exp. 1-3). 
Stable cells expressing SH-SY5Y-CLN5-CTAP-Puro were subjected to tandem affinity 
purification coupled to mass spectrometry (TAP-MS) and processed similarly as indicated for 
Table 1, except that raw data is shown without filtration steps. SAINT analysis of CLN5 baits 
is based on three experiments and empty CTAP-Puro vector is used as a negative control.  
Scifo et al. 2013 Drafting the CLN3 Interactome 
 39
Supplementary Table 6: List of all known interactions of CLN3 and CLN5 proteins. 
The combined network was compiled using interactions derived from this work, database 
assigned and literature published interactions.  
 
Supplementary Table 7: Predicted functional links between CLN3-CLN5 network 
proteins. 
CLN3 / CLN5 IP identified in TAP-MS experiments were used as input in the functional 
coupling analysis using FunCoup (http://FunCoup.sbc.su.se) gene / protein functional 
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                                                           Table 1. SAINT analysis of CLN3-IP recovered by TAP-MS  
Bait Prey Spectrala Control AvgPb  Commentsc 
CLN3 IMMT 45, 32, 4 0, 0, 0 1 CLN3 HCIP_autophagy network 
CLN3 SLC25A4 74, 23, 15 0, 0, 0 1 Novel CLN3 IP  
CLN3 GCN1L1 40, 40, 0 0, 0, 0 1 CLN3 HCIP_autophagy network 
CLN3 PRKDC 32, 20, 0 0, 0, 0 1 CLN3 HCIP_autophagy network 
CLN3 SLC25A6 82, 0, 20 0, 0, 0 0.9990 Novel CLN3 IP  
CLN3 ATP2A2 13, 24, 0 0, 0, 0 0.9990 Novel CLN3 IP  
CLN3 XPO1 13, 18, 0 0, 0, 0 0.9980 CLN3 HCIP_autophagy network 
CLN3 CPT1A 15, 18, 4 0, 0, 0 0.9970 CLN3 HCIP_autophagy network 
CLN3 SLC25A5 75, 0, 18 0, 0, 0 0.9950 Novel CLN3 IP  
CLN3 SFXN3 15, 12, 3 0, 0, 0 0.9880 Novel CLN3 IP  
CLN3 HSD17B12 10, 13, 0 0, 0,0 0.9880 CLN3 HCIP_autophagy network 
CLN3 TECR 6, 10, 0 0, 0, 0 0.9850 Novel CLN3 IP 
CLN3 SLC25A13 27, 25, 6 0, 0, 0 0.9820 Novel CLN3 IP  
CLN3 RPN2 5, 16, 0 0, 0, 0 0.9820 CLN3 HCIP_autophagy network 
CLN3 PHGDH 18, 14, 13 0, 0, 0 0.9500 CLN3 HCIP_autophagy network 
CLN3 RPN1 4, 7, 0 0, 0, 0 0.9420 Novel CLN3 IP  
CLN3 TMEM33 4, 8, 3 0, 0, 0 0.9310 Novel CLN3 IP 
CLN3 SFXN1 10, 4, 0 0, 0, 0 0.9290 Novel CLN3 IP  
CLN3 C19orf70 3, 4, 0 0, 0, 0 0.9170 Novel CLN3 IP 
CLN3 SSR4 2, 9, 0 0, 0, 0 0.902 Novel CLN3 IP  
CLN3 SAMM50 3, 4, 0 0, 0, 0 0.8950 Novel CLN3 IP  
CLN3 CDS2 2, 5, 0 0, 0, 0 0.8910 Novel CLN3 IP  
CLN3 UQCRC2 6, 3, 0 0, 0, 0 0.8820 Novel CLN3 IP 
CLN3 COX15 3, 4, 0 0, 0, 0 0.8770 CLN3 HCIP_autophagy network 
CLN3 PTPLAD1 4, 8, 4 0, 0, 0 0.8650 Novel CLN3 IP  
CLN3 SLC25A11 2, 5, 0 0, 0, 0 0.8530 CLN3 HCIP_autophagy network 
CLN3 SEC61A1 2, 5, 0 0, 0, 0 0.8480 Novel CLN3 IP  
CLN3 STRA6 4, 3, 0 0, 0, 0 0.8330 Novel CLN3 IP 
CLN3 DDOST 2, 3, 0 0, 0, 0 0.7750 CLN3 HCIP_autophagy network 
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Table 1. Continued 
Bait Prey Spectrala Control AvgPb  Commentsc 
CLN3 SLC35B2 2, 3, 0 0, 0, 0 0.7740 Novel CLN3 IP  
CLN3 SLC25A3 14, 0, 11 0, 0, 0 0.7440 Novel CLN3 IP  
CLN3 EMD 4, 2, 0 0, 0, 0 0.7310 Novel CLN3 IP  
CLN3 FADS2 7, 2, 0 0, 0, 0 0.7310 Novel CLN3 IP 
CLN3 TFRC 2, 3, 0 0, 0, 0 0.692 Novel CLN3 IP  
CLN3 CSE1L 2, 3, 0 0, 0, 0 0.603 Novel CLN3 IP  
CLN3 ARF4    11     0 0.9920 Novel CLN3 IP 
CLN3 DBH    8     0 0.9720 Novel CLN3 IP 
CLN3 CALU    5     0 0.9680 Novel CLN3 IP 
CLN3 AUP1    8     0 0.9680 CLN3 HCIP_autophagy network 
CLN3 DPM1    6     0 0.9640 Novel CLN3 IP  
CLN3 KIAA0368    5     0 0.9560 CLN3 HCIP_autophagy network 
CLN3 XPO5    5     0 0.9560 Novel CLN3 IP  
CLN3 SLC25A1    6     0 0.9500 Novel CLN3 IP  
CLN3 SLC25A22    6     0 0.9500 CLN3 HCIP_autophagy network 
CLN3 RCN2    5     0 0.9500 Novel CLN3 IP  
CLN3 SLC25A10    5     0 0.9480 CLN3 HCIP_autophagy network 
CLN3 LPHN2    6     0 0.9440 Novel CLN3 IP 
CLN3 FKBP8    4     0 0.9440 Novel CLN3 IP  
CLN3 ARF5    4     0 0.9420 Novel CLN3 IP 
CLN3 ERLIN2    4     0 0.9340 Novel CLN3 IP  
CLN3 ATP1A1    4     0 0.9320 Novel CLN3 IP  
CLN3 ARF3    4     0 0.9260 Novel CLN3 IP 
CLN3 SCAMP3    4     0 0.9220 Novel CLN3 IP  
CLN3 NUP205    5     0 0.9200 CLN3 HCIP_autophagy network 
CLN3 ATP5L    3     0 0.9180 Novel CLN3 IP 
CLN3 FAR1    3     0 0.9120 Novel CLN3 IP 
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Table 1. Continued 
Bait Prey Spectrala Control AvgPb  Commentsc 
CLN3 ARMC6    3     0 0.9120 Novel CLN3 IP 
CLN3 LPGAT1    3     0 0.9040 Novel CLN3 IP 
aSpectral indicates Spectral counts in each biological replicate.  
bAvgP is the average of individual probabilities. AvgP ? 0.5 is based on 2/3 experiments, except for  
single hits ? 0.9.    
cNovel CLN3 IP- novel interacting partner of CLN3 identified in this work.  
CLN3 HCIP_autophagy network- CLN3 high confidence interacting partner, previously identified by  
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                                  Table 2. SAINT analysis of CLN5-IP recovered by TAP-MS  
Bait Prey Spectrala     Control AvgPb  Commentsc 
CLN5 SEL1L 34, 12, 49 0, 0, 0 1 Novel CLN5 IP_this study 
CLN5 GANAB 25, 4, 52 0, 0, 0 1 CLN3 HCIP_autophagy network 
CLN5 SLC25A4 0, 25, 20 0, 0, 0 1 CLN3 IP_this study 
CLN5 CLGN 26, 4, 58 0, 0, 0 1 Novel CLN5 IP_this study 
CLN5 CANX 43, 19, 43     0, 0, 0 0.9990 Novel CLN5 IP_this study 
CLN5 OS9 28, 9, 30 0, 0, 0 0.9990 Novel CLN5 IP_this study 
CLN5 DBH 0, 18, 12 0, 0, 0 0.9980 CLN3 IP_this study 
CLN5 SFXN3 0, 6, 13 0, 0, 0 0.9970 CLN3 IP_this study 
CLN5 RCN2 0, 7, 12 0, 0, 0 0.9950 CLN3 IP_this study 
CLN5 CALR 10, 0, 11 0, 0, 0 0.9880 Novel CLN5 IP_this study 
CLN5 CALU 0, 5, 13 0, 0,0 0.9880 CLN3 IP_this study 
CLN5 SLC25A13 0, 6, 26 0, 0, 0 0.9850 CLN3 HCIP_autophagy network 
CLN5 ARHGAP36 5, 0, 10 0, 0, 0 0.9820 Novel CLN5 IP_this study 
CLN5 SLC25A22 0, 5, 8 0, 0, 0 0.9820 CLN3 HCIP_autophagy network 
CLN5 SLC25A1 0, 2, 12 0, 0, 0 0.9500 CLN3 HCIP_autophagy network 
CLN5 FBXO6 4, 3, 0 0, 0, 0 0.9420 Novel CLN5 IP_this study 
CLN5 FBXO27 3, 0, 4 0, 0, 0 0.9310 Novel CLN5 IP_this study 
CLN5 ATP2A2     19 0 1 CLN3 IP_this study 
CLN5 SLC25A5     34 0 0.9980 CLN3 IP_this study 
CLN5 SLC25A6     35 0 0.9980 CLN3 IP_this study 
CLN5 PHGDH     5 0 0.9660 CLN3 HCIP_autophagy network 
CLN5 ATP1A3     8 0 0.9640 Novel CLN5 IP_this study 
CLN5 ARF4     6 0 0.9580 CLN3 IP_this study 
CLN5 CDIPT     6 0 0.9500 Novel CLN5 IP_this study 
CLN5 SEC61A1     7 0 0.9500 CLN3 IP_this study 
CLN5 HMGCS1     4 0 0.9280 Novel CLN5 IP_this study 
CLN5 XPO1     6 0 0.9260 CLN3 HCIP_autophagy network 
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Table 2. Continued 
Bait Prey Spectrala Control AvgPb  Commentsc 
CLN5 RPN1     6      0 0.9220 CLN3 IP_this study 
CLN5 SPNS1     5      0 0.9200 Novel CLN5 IP_this study 
CLN5 SLC25A11     6      0 0.9120 CLN3 HCIP_autophagy network 
CLN5 CDS2     5      0 0.9000 CLN3 IP_this study 
aSpectral indicates Spectral counts in each biological replicate.  
bAvgP is the average of individual probabilities. AvgP ? 0.5 is based on 2/3 experiments,  
except for single hits ? 0.9.    
cCLN3 IP_this study- CLN3 interacting partner identified in this work.  
CLN5 IP_this study- CLN5 interacting partner identified in this work. 
CLN3 HCIP_autophagy network- CLN3 high confidence interacting partner, previously identified by Behrends et 
al. 2010, Nature, 2010;466(7302):68-76. 
 











